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Abstract 
Background 
Alternative complement activation is involved in the pathogenesis of anti-neutrophil cytoplasm 
antibody-associated vasculitis. Glucocorticoids contribute to the morbidity and mortality of 
vasculitis. The aim was to determine if avacopan (CCX168), an orally-administered, selective 
C5a receptor inhibitor, could replace oral glucocorticoids without compromising efficacy. 
 
Methods 
In this randomized, placebo-controlled trial, adults with newly-diagnosed or relapsing vasculitis 
received placebo plus prednisone starting at 60 mg daily (control group), avacopan 30 mg twice 
daily plus reduced dose prednisone, 20 mg daily, or avacopan 30 mg twice daily without 
prednisone. All patients received either cyclophosphamide or rituximab. The primary efficacy 
measure was the proportion of patients achieving a reduction in Birmingham Vasculitis Activity 
Score by week 12 of at least 50% and no worsening in any body system. 
 
Results 
We enrolled 67 patients, 23 in control, and 22 in each of the avacopan groups. Clinical response 
at week 12 was achieved in 14 of 20 (70.0%) patients in control, 19 of 22 (86.4%) in avacopan 
plus reduced dose prednisone group (difference from control 16.4%; two-sided 90% confidence 
limit -4.3, 37.1%, p=0.002 for non-inferiority), and 17 of 22 (81.0%) in avacopan without 
prednisone group (difference from control 11.0%; two-sided 90% confidence limit -11.0, 32.9%, 
p=0.01 for non-inferiority). Adverse events occurred in 21 of 23 (92%) patients in control versus 
19 of 22 (86%) patients in the first avacopan, and 21 of 22 (96%) patients in the second avacopan 
group.  
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Conclusions 
C5aR inhibition with avacopan was effective in replacing high dose glucocorticoids in treating 
vasculitis. 
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Introduction 
Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a serious, often life-
threatening disease linked to auto-antibodies to proteinase 3 (PR3-ANCA) and myeloperoxidase 
(MPO-ANCA). Despite the current standard treatment with high dose glucocorticoids and either 
cyclophosphamide or rituximab, patients have a nine-fold increased mortality risk in the first year 
compared to healthy controls, attributed to infection, vasculitis activity, and renal disease.1 
Current therapies, rather than the underlying disease itself, contribute more than half of this 
increased risk.2 Fifteen to 38 percent of patients develop end-stage renal disease within 5 years.3-7 
Glucocorticoids are associated with increased infection risk8-10 and progressive organ damage.11 
Complement 5a (C5a) and C5a receptor (C5aR, or CD88) play a central role in the pathogenesis 
of AAV.12-14 C5a can prime and activate neutrophils15 which release C5a when stimulated by 
inflammatory cytokines such as TNFα.16 C5a, acting on C5aR, is a potent neutrophil 
chemoattractant and agonist17 and can decrease neutrophil deformability, slowing their ability to 
traverse small blood vessels, particularly in the presence of ANCA.18 C5a also activates vascular 
endothelial cells, promoting their retraction and increased vascular permeability.19,20 
Avacopan, previously called CCX168, is an orally administered small-molecule C5aR antagonist 
that blocks the effects of C5a21, and prevented the development of glomerulonephritis induced by 
anti-myeloperoxidase antibodies in a murine model of AAV.22 We therefore tested the efficacy 
and safety of avacopan in patients with active AAV, treated concomitantly with 
cyclophosphamide or rituximab.  
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Results 
The study ran from 12 October 2011 (first patient enrolled) until 18 January 2016. Patient 
disposition is shown in Figure 1. The demographics and baseline characteristics were statistically 
similar among the three groups (no p-values < 0.05 for comparisons across groups), except for 
high baseline serum creatinine on BVAS, with 15 of 23 subjects in the control group compared to 
6 of 22 in the avacopan plus no prednisone group (Table 1).  
Treatment responses occurred in 86% and 81% of the avacopan with reduced dose, and avacopan 
with no prednisone groups, respectively, and in 70% in the high dose glucocorticoid (control) 
group. Both avacopan groups met non-inferiority criteria (p = 0.002 for avacopan with reduced 
dose prednisone vs. control and p = 0.01 for avacopan with no prednisone vs. control; Table 2). 
The avacopan treatment response was observed across subgroups (Supplemental Table 2), and 
individual patient Birmingham Vasculitis Activity Score (BVAS) data showed a more consistent 
response in the two avacopan groups compared to control (Figure 2A); p = 0.04 at week 4 and p 
= 0.09 at week 12 for all avacopan compared to prednisone control. Remission (BVAS 0) at week 
4 that was sustained to week 12 occurred in 9 of 43 (21%) patients on avacopan compared to 1 of 
20 (5%) in the control group (Figure 2A and Table 2); p = 0.10 for all avacopan compared to 
prednisone control and p = 0.04 for avacopan with no prednisone compared to prednisone 
control. Secondary end point results are summarized in Figures 2B to 2G, and in Table 2. The 
mean percent decrease in BVAS at week 4 in the avacopan groups was comparable to the control 
group change at week 12. The mean increase in vasculitis damage index (VDI) between entry and 
week 12 was 0.3 and 0.2 in the two avacopan groups, respectively, compared to 0.7 in the control 
group (not statistically different).  
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Albuminuria improved early in both avacopan groups and the improvements were statistically 
greater than control at week 4 for both avacopan groups, and in the avacopan with reduced 
prednisone group vs. control group at week 12 (Table 2). Estimated glomerular filtration rate 
(eGFR) and hematuria improved similarly across all three groups. Urinary creatinine-corrected 
monocyte chemoattractant protein-1 (MCP-1), improved more in the avacopan compared to the 
control group at week 4 and 12, and C-reactive protein levels decreased similarly across groups 
(Table 2). 
Health-related quality of life, including physical and mental components, improved more with 
avacopan compared to control based on the Medical Outcomes Survey Short Form-36 (SF-36) 
and EuroQOL-5D-5L (EQ-5D-5L) instruments (Table 2 and Supplemental Table 3). 
Three patients received rescue glucocorticoids during the treatment period, one in the control 
group and two in the avacopan without prednisone group.  
At the end of the 12-week treatment period, 3, 3, and 2 patients in the control, avacopan plus 
reduced dose prednisone, and avacopan without prednisone groups, respectively, were ANCA-
negative.   
The control and avacopan plus reduced prednisone groups continued to receive prednisone for the 
first 8 and 2 weeks, respectively, of the 12-week follow-up period, whereas the avacopan without 
prednisone group received no prednisone (Supplemental Table 1). Sixteen of 20 (80%), 17 of 22 
(77%), and 15 of 21 (71%) patients in the control, avacopan plus reduced dose prednisone, and 
avacopan without prednisone groups, respectively, had a BVAS decrease of at least 50% at week 
24. The BVAS mean change at week 24 was -83, -87, and -85 percent, respectively. eGFR at 
week 24 was 54, 59, and 55 mL/min/1.73 m2, respectively. The UACR mean change at week 24 
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was -48%, -61%, and -30%, respectively. At the end of the 12-week follow-up period, 2, 5, and 6 
patients, respectively, were ANCA-negative. 
The incidence of all adverse events and Grade 3 or greater adverse events was similar across 
groups (Table 3). There were no deaths during the study. Adverse events were consistent with the 
underlying medical conditions and concomitant therapies. Four of 23 (17%) patients in the 
control group and 11 of 44 (25%) patients receiving avacopan had serious adverse events. When 
all adverse events are taken into account, 2, 1, and 3 patients in the control, avacopan plus 
reduced dose prednisone group, and avacopan without prednisone groups, respectively, reported 
vasculitis (worsening): two of relapse of renal vasculitis in the control group, one of vasculitis 
worsening in the avacopan plus low dose prednisone group, and three of relapse of microscopic 
polyangiitis, flare of joint vasculitis, and relapse of renal vasculitis, respectively, in the avacopan 
plus no prednisone group. One patient in each group had a serious infection: pneumonia, febrile 
infection (no source identified), and respiratory infection in the control, avacopan plus reduced 
dose prednisone group, and avacopan without prednisone groups, respectively. No events of 
sepsis were reported. One patient, in the avacopan without prednisone group, with a medical 
history of alcohol abuse and concomitant treatment with cyclophosphamide, co-trimoxazole, and 
pantoprazole had hepatic and pancreatic enzyme elevations. Study drug was discontinued in this 
patient, who recovered. Another patient in this group had worsening of a pre-existing skin rash.  
There was a lower incidence of adverse effects potentially related to glucocorticoid use in 
patients receiving avacopan, 15 of 44 (34%), compared to control, 15 of 23 (65%); p = 0.02. This 
difference was primarily driven by a lower incidence of psychiatric disorders and new-onset or 
worsening diabetes (Table 3). 
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More patients in the avacopan without prednisone group, but not the avacopan plus reduced dose 
prednisone group, had Grade 2 or 3 lymphopenia during the 12-week treatment period compared 
to control (Table 3). One patient in the avacopan plus reduced dose prednisone group had an 
increase in creatine phosphokinase. This was not accompanied by any signs or symptoms of 
muscle injury, and the values returned to normal with uninterrupted avacopan treatment. 
Treatment was stopped in the patient with elevated liver and pancreatic enzymes (in the avacopan 
without prednisone group), who also had an elevated bilirubin level, which recovered.  
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Discussion 
High dose glucocorticoids have for half a century been considered as indispensable in the 
treatment of AAV, despite their well-documented toxicities.23,2,8-11 In this study we show that 
inhibition of the C5a receptor may be an alternative to use of oral glucocorticoids, and that C5a is 
an important inflammatory mediator in AAV. 
Vasculitis activity is inadequately controlled in many patients. In a clinical trial comparing 
rituximab and cyclophosphamide, the primary outcome measure of disease remission at 6 months 
was not achieved in 42% of patients24, due to disease flares (36%), uncontrolled disease, 
discontinuation due to adverse events, or inability to completely taper glucocorticoids.25  
This clinical trial met its primary end point indicating that the orally administered C5aR inhibitor 
avacopan can replace high dose glucocorticoids effectively and safely in patients with AAV. 
Several lines of evidence suggest that avacopan might also add benefit. In addition to avoiding 
glucocorticoid side effects, individual patient BVAS data suggest a rapid, consistent clinical 
response in patients receiving avacopan. Early efficacy with avacopan was further substantiated 
by a rapid improvement in albuminuria, which is common in patients with AAV and is a 
prognostic factor for poor renal outcome.26,27 Therefore, the avacopan benefit on albuminuria 
may translate into improved preservation of renal function. Results from the 12-week follow-up 
period indicate that there was no immediate rebound effect following withdrawal of avacopan 
treatment.    
A high level of the renal inflammation marker, urinary monocyte chemoattractant protein-1, also 
correlates with poorer outcomes in patients with active renal vasculitis and other renal 
diseases.28-31 Base line urinary MCP-1:creatinine ratio was 3- to 5-fold higher than the upper limit 
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of the reference range for healthy subjects32 and renal inflammation improved rapidly and to a 
greater extent with avacopan compared to control, which may lead to less glomerular and renal 
tubular damage. eGFR and hematuria improved similarly in all three groups over the 12-week 
treatment period, indicating that improvement in renal function in patients receiving avacopan did 
not require high dose glucocorticoids. 
Patients with AAV may present with symptoms such as fatigue, fever, headache, arthralgia, and 
myalgia, which negatively impact quality of life. Results showed that avacopan broadly improved 
various aspects of patients’ well-being, albeit from a small sample of patients. This may translate 
into less work absenteeism, fewer visits to the doctor, and ultimately reduced health care cost. 
Avacopan appeared to be well tolerated and safe in this trial. There was a lower incidence of 
adverse effects related to glucocorticoid use, such as new onset diabetes, psychiatric disorders, 
weight gain, fracture, and cataract in the avacopan treatment groups compared to control, 
indicating that using avacopan instead of glucocorticoids may avoid these side effects. Curiously, 
lymphopenia was observed more commonly in the avacopan without prednisone group, but not 
the avacopan plus reduced dose prednisone group, compared to control. This argues against a 
detrimental avacopan effect. A more plausible explanation is that the absence of prednisone in the 
avacopan without prednisone group is unmasking the known lymphopenic effect of 
cyclophosphamide and rituximab, because in the short term, glucocorticoids cause an increase in 
lymphocyte count.33  
The study has limitations. It is relatively small and the treatment duration was short. The 12-week 
treatment period was driven by the available toxicology data at the time of study launch. By 
necessity, the trial was performed in three sequential steps, rather than as a concurrent, parallel 
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group trial, since glucocorticoids could not be replaced completely without having some evidence 
of the efficacy of avacopan. A relatively small number of patients received rituximab rather than 
cyclophosphamide concomitant treatment; rituximab was not yet approved at the time of study 
launch. Treatment response instead of remission based on BVAS was used as the primary end 
point in this study because of the short treatment duration. There is precedence for using such a 
response (or partial remission) endpoint based on BVAS34,35. The glucocorticoid tapering 
schedule is relatively rapid compared to the RAVE study24, but is consistent with the 
RITUXVAS study conducted in Europe at the same time36. There is no consensus glucocorticoid 
tapering schedule in AAV, and the current EULAR/ERA-EDTA guidance is to taper 
glucocorticoids more rapidly (7.5 to 10 mg prednisone by 3 months) to avoid side effects37. Since 
this was the first study with avacopan in AAV, patients with severe end-organ manifestations 
needed to be excluded; this may limit the generalizability of the findings. 
Based on the very promising results from this study, avacopan development was advanced to 
Phase 3. 
  
 13 
Concise Methods 
Study design and patients 
We performed a randomized, double-blind, placebo-controlled trial at 32 centers in Europe. The 
aim was to reduce or replace glucocorticoid treatment with avacopan without compromising 
efficacy in treating AAV. Since there were no available data prior to the study regarding the 
ability of avacopan to safely replace glucocorticoids, the original primary objective of the study 
was to assess the safety of avacopan. Therefore, the study was done in a stepwise manner with 
three sequential steps. In step 1, we tested whether avacopan permitted a reduced oral prednisone 
dose. If there were no unexpected serious adverse events or an excess of glucocorticoid rescue 
events, step 2 would be performed. In step 2, we tested whether avacopan could replace oral 
prednisone entirely. If successful, step 3 would follow, which was to be an expansion of the study 
size. After successful completion of the first two steps, an efficacy endpoint based on treatment 
response was added. Twelve weeks treatment with avacopan was followed by 12 weeks without 
study drug. The prednisone tapering schedule is shown in Supplemental Table 1. 
The inclusion and exclusion criteria are provided in the Supplement.  
The trial was performed in accordance with the Declaration of Helsinki and Good Clinical 
Practice guidelines. Ethics committees and institutional review boards approved the research 
protocol. All patients gave written informed consent before entry.  
Randomization and Treatment 
After screening, patients were stratified based on having newly diagnosed or relapsing disease 
(all three steps), and by PR3 or MPO-ANCA, and cyclophosphamide or rituximab treatment (step 
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3). In step 1, 12 patients were enrolled and randomly assigned in a 2 to 1 ratio to receive 30 mg 
avacopan twice daily plus 20 mg prednisone, or placebo avacopan plus 60 mg prednisone. In step 
2, 14 patients were enrolled and randomly assigned in a 2 to 1 ratio to receive 30 mg avacopan 
twice daily without prednisone or placebo avacopan plus 60 mg prednisone. All patients in steps 
1 and 2 received cyclophosphamide intravenously at 15 mg/kg up to 1.2 g on day 1 and weeks 2, 
4, 8, and 12, followed by oral azathioprine at a target dose of 2 mg/kg/day from week 14 to 24. 
Rituximab was not allowed in steps 1 and 2, because it was not approved at the time of study 
launch. The cyclophosphamide dose was adjusted based on age, eGFR, and white blood cell 
(WBC) count (see Supplement). In step 3, 41 patients were randomly assigned (1:1:1) to receive 
30 mg avacopan twice daily plus 20 mg prednisone, 30 mg avacopan twice daily plus placebo 
prednisone, or placebo avacopan plus 60 mg prednisone. All patients in step 3 received either 
cyclophosphamide followed by azathioprine as described above, or intravenous rituximab 375 
mg/m2/week for 4 weeks.  
Stratification and randomization were performed centrally via an interactive voice response 
system using a minimization algorithm to maintain balance among the treatment groups with 
respect to strata and study center.38 
Patients and all study personnel were masked to treatment allocation. All study drugs had 
matching active and placebo capsules, identical bottles and boxes. 
Study assessments are provided in the Supplement. 
End points 
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The primary efficacy end point was the proportion of patients with a treatment response at week 
12 defined as a BVAS decrease from base line of at least 50 percent plus no worsening in any 
body system. Patients receiving rescue glucocorticoids were considered non-responders. 
Secondary endpoints included the proportion of patients with a renal response, defined as an 
improvement in eGFR calculated using the Modified Diet in Renal Disease equation (see 
supplement), hematuria, and albuminuria at week 12, the proportion of patients with disease 
remission (BVAS 0), change from baseline in BVAS, eGFR, urinary albumin:creatinine ratio 
(UACR), urinary red blood cell count, urinary monocyte chemoattractant protein-1 (MCP-
1):creatinine ratio, VDI, SF-36 version 2, EQ-5D-5L, and rescue glucocorticoid use. The week 24 
follow-up data were summarized. 
Statistical analysis 
The planned study size was 60 patients. This study size was based on feasibility given that AAV 
is an orphan disease. Efficacy analyses were conducted on the intention-to-treat (ITT) population 
defined as all patients with at least one post base line on-treatment BVAS assessment. The safety 
population included all randomized patients who received at least one dose of study drug. 
For the primary efficacy end point, the proportion of patients achieving disease response was 
calculated for the comparison between each avacopan group against control. If the lower bound 
of the 1-sided 95% confidence interval for the difference (avacopan minus control) was greater 
than -0.20, the respective avacopan group would be considered not inferior to control. A 20 
percent non-inferiority boundary and a 1-sided 95% confidence interval were considered 
appropriate in the context of a relatively small Phase 2 clinical trial in an orphan disease setting. 
There is also precedent for selecting a 20 percent non-inferiority boundary in AAV24.  If the 
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lower bound was greater than 0.0, the respective avacopan group would be considered superior to 
control. As pre-specified, results from all three study steps were combined for the primary 
analysis. 
Continuous variables were analyzed using a mixed effects model for repeated measures with 
treatment group, study visit, treatment-by-visit interaction, and randomization strata as factors, 
and base line as covariate. Patients were considered as repeated measure units over visits. Data 
that were not normally distributed, e.g., UACR, were log-transformed before analysis. 
The study was registered with ClinicalTrials.gov (NCT01363388).  
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Figure Legends 
 
Figure 1. Patient Disposition. Of 87 patients screened, 67 were enrolled. The main reasons for 
study exclusion were insufficient disease activity, low white blood cell count, and severe disease 
activity. BVAS = Birmingham Vasculitis Activity Score, ANCA = anti-neutrophil cytoplasm 
antibody, eGFR = estimated glomerular filtration rate, PT = prothrombin time, PTT = partial 
thromboplastin time, AE = adverse event.  
 
Figure 2. Efficacy Profile of Avacopan. (A) Birmingham Vasculitis Activity Score percent 
change from base line for each patient, presented by treatment group; (B) Birmingham Vasculitis 
Activity Score mean ± SEM percent change from base line for placebo plus high dose 
prednisone, n = 20 (♦), avacopan plus reduced dose prednisone, n = 22 (■), and avacopan 
without prednisone, n = 21 (▲); (C) First morning urinary albumin to creatinine ratio percent 
change from base line, calculated as 100 X (geometric mean at the study visit) / (geometric mean 
at base line) for placebo plus high dose prednisone, n = 20 (♦), avacopan plus reduced dose 
prednisone, n = 22 (■), and avacopan without prednisone, n = 20 (▲); * P < 0.05, ** P < 0.01, 
and *** P < 0.001 for avacopan compared to control by mixed effects model for repeated 
measures analysis with treatment group, study visit, treatment-by-visit interaction, and 
randomization strata as factors, and base line as covariate. (D) First morning urinary monocyte 
chemoattractant protein-1 to creatinine ratio percent change from base line, calculated as 100 X 
(geometric mean at the study visit) / (geometric mean at base line) for placebo plus high dose 
prednisone, n = 20 (♦), avacopan plus reduced dose prednisone, n = 22 (■), and avacopan 
without prednisone, n = 21 (▲); ** P < 0.01, and *** P < 0.001 for avacopan compared to 
control by mixed effects model for repeated measures analysis with treatment group, study visit, 
treatment-by-visit interaction, and randomization strata as factors, and base line as covariate. (E) 
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and (F) Health-related Quality of Life measurement Medical Outcomes Study Short Form-36 
version 2 Physical Functioning and Role Emotional components, respectively, expressed as mean 
± SEM over the course of the treatment period for placebo plus high dose prednisone, n = 10 (♦), 
avacopan plus reduced dose prednisone, n = 14 (■), and avacopan without prednisone, n = 9 (▲); 
the scale ranges from 0 to 100, from low to high functioning; * P < 0.05 for avacopan compared 
to control regarding change or percent change from base line by mixed effects model for repeated 
measures analysis with treatment group, study visit, treatment-by-visit interaction, and 
randomization strata as factors, and base line as covariate. (G) Health-related Quality of Life 
measurement EuroQOL-5D-5L visual analogue scale expressed as mean ± SEM for placebo plus 
high dose prednisone, n = 10 (♦), avacopan plus reduced dose prednisone, n = 14 (■), and 
avacopan without prednisone, n = 9 (▲); the scale is measured from 0 to 100, from low to high 
self-perception of health status;  * P < 0.05 for avacopan compared to control regarding change 
from base line by mixed effects model for repeated measures analysis with treatment group, study 
visit, treatment-by-visit interaction, and randomization strata as factors, and base line as 
covariate.   
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Table 1. Demographics and Baseline Characteristics* 
Category Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 
mg prednisone 
(N=22) 
Avacopan 
without 
prednisone 
(N=22) 
Age (years) 59.1±14.0 57.0±14.2 57.4±14.0 
Sex, Male/Female—no. 17/6 14/8 16/6 
Race, White—no. 23 22 22 
Duration of vasculitis (months) 0 (0-162) 0 (0-61) 1 (0-108) 
Body mass index (kg/m2) 27.3±7.1 24.9±4.0 26.5±4.7 
Disease history 
Newly Diagnosed—no. (%) 18 (78) 15 (68) 16 (73) 
Relapsed Disease—no.  (%) 5 (22) 7 (32) 6 (27) 
ANCA type 
Anti-myeloperoxidase positive—no. 
(%) 
10 (43) 12 (55) 13 (59) 
Anti-proteinase 3 positive—no. (%) 11 (48) 10 (45) 8 (36) 
Both anti-myeloperoxidase and anti- 
proteinase 3 positive—no. (%) 
1 (4) 0 0 
ANCA equivocal or negative—no. (%) 1 (4%) 0 1 (5%) 
Disease type 
Granulomatosis with polyangiitis—no. 
(%) 
10 (44) 11 (50) 12 (55) 
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Category Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 
mg prednisone 
(N=22) 
Avacopan 
without 
prednisone 
(N=22) 
Microscopic polyangiitis—no. (%) 12 (52) 11 (50) 10 (45) 
Unknown—no. (%) 1 (4) 0 0 
Disease assessment scores 
Birmingham Vasculitis Activity Score† 13.2±5.8 14.3±6.0 13.8±6.4 
Vasculitis Damage Index 1.2±1.4 0.9±1.5 0.5±1.2 
Organ involvement 
Renal involvement—no. (%) 23 (100) 21 (95) 21 (95) 
Rise in serum creatinine—no. (%) 2 (9) 0 0 
High serum creatinine—no. (%) 15 (65) 11 (50) 6 (27) ‖ 
Hematuria—no. (%) 22 (96) 20 (91) 21 (95) 
Proteinuria—no. (%) 18 (78) 20 (91) 16 (73) 
Hypertension—no. (%) 3 (13) 5 (23) 2 (9) 
Pulmonary involvement—no. (%) 9 (39) 8 (36) 7 (32) 
Constitutional signs or symptoms‡—
no. (%) 
19 (83) 17 (77) 16 (73) 
Cutaneous involvement—no. (%) 4 (17) 1 (5) 4 (18) 
Mucous membranes and eyes—no. (%) 1 (4) 1 (5) 4 (18) 
Ear, nose, and throat—no. (%) 9 (39) 5 (23) 8 (36) 
Cardiovascular involvement—no. (%) 0 1 (5)  2 (9) 
Neurological involvement—no. (%) 3 (13) 5 (23) 2 (9) 
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Category Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 
mg prednisone 
(N=22) 
Avacopan 
without 
prednisone 
(N=22) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2)§ 
47.6±15.1 52.5±26.7 54.7±19.6 
Urinary albumin:creatinine ratio (mg/g)¶ 354 (28-5962) 279 (24-2459) 283 (25-3051) 
Prior medications of interest 
Systemic glucocorticoids—no. (%) 11 (48) 14 (64) 11 (50) 
Prednisone-equivalent daily dose 
per patient (mg) 
53 49 44 
IV glucocorticoids—no. (%) 5 (25) 9 (41) 5 (23) 
Immunosuppressants including 
azathioprine, methotrexate, or 
mycophenolate mofetil—no. (%) 
2 (9) 4 (18) 3 (14) 
Cyclophosphamide or rituximab—no. 0 0 0 
* Plus-minus values are mean±SD 
† The Birmingham Vasculitis Activity Score version 3 was used to capture vasculitis disease activity. The 
score ranges from 0 to 63 with higher scores denoting more severe disease activity. 
‡ Constitutional signs and symptoms included weight loss, fever, arthralgia, and myalgia. 
§ Estimated glomerular filtration rate based on Modified Diet in Renal Disease equation derived from 
serum creatinine (see supplement). 
¶ Urinary albumin:creatinine ratio values are geometric means and ranges. 
‖ p < 0.05 for comparison of avacopan vs. control; Fisher’s exact test. 
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Table 2. Efficacy Results for 12-Week Treatment Period* 
  Placebo plus 60 mg 
prednisone control 
(N=20) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=21) 
Birmingham Vasculitis Activity Score and Vasculitis Damage Index end points 
Primary endpoint: Treatment response† at 
week 12—no. (%) 
14 (70.0) 19 (86.4) 17 (81.0) 
Difference in percentage compared to 
control 
Two-sided 90% confidence interval for 
difference in percentage, avacopan minus 
control 
-- 
 
-- 
16.4 
 
-4.3, 37.1 
11.0 
 
-11.0, 32.9 
Birmingham Vasculitis Activity Score Actual %Change Actual %Change Actual %Change 
Base line 13.6±1.4 -- 14.3±1.3 -- 13.6±1.4 -- 
Week 4 6.6±1.2 -40±12 4.9±0.7 -64±5 5.3±1.3 -61±9 
Week 12 5.0±1.6 -56±14 2.6±0.7 -79±5 3.6±1.1 -73±7 
Vasculitis Damage Index  Actual Change Actual Change Actual Change 
Base line 1.2±0.3 -- 0.9±0.3 -- 0.5±0.3 -- 
Week 12 1.8±0.4 0.7±0.2 1.2±0.3 0.3±0.1 0.8±0.3 0.2±0.1 
Remission (BVAS 0) at week 12—no. (%) 8 (40) 10 (45) 7 (33) 
Remission at week 4 sustained through week 
12—no. (%) 
1 (5) 3 (14) 6 (29)‖ 
Renal end points 
 N=20 N=18 N=18 
Renal response‡ at week 12—no. (%) 8 (40) 10 (56) 6 (33) 
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  Placebo plus 60 mg 
prednisone control 
(N=20) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=21) 
Urinary albumin:creatinine ratio (milligram 
per gram creatinine) in patients with 
albuminuria at base line 
N=20 N=22 N=20 
 Actual %Change Actual %Change Actual %Change 
Base line 318 -- 279 -- 280 -- 
Week 4 355 15 168 -40§ 142 -47¶ 
Week 12 252 -21 127 -56§ 158 -43 
Estimated glomerular filtration rate (milliliter 
per minute per 1.73 square meters 
Actual Change Actual Change Actual Change 
Base line 47.2±3.5 -- 52.5±5.7 -- 54.8±4.4 -- 
Week 4 45.8±3.1 -0.8±2.0 54.5±4.5 2.0±2.3 53.5±4.8 -1.2±3.7 
Week 12 52.8±3.6 5.6±2.3 56.2±4.3 6.0±2.3 56.1±5.2 0.8±2.2 
Urinary red blood cell count (cells per high 
power field) in patients with hematuria at 
base line 
N=20 N=20 N=19 
 Actual %Change Actual %Change Actual %Change 
Base line 22 -- 26 -- 17 -- 
Week 4 5 -76 7 -72 6 -65 
Week 12 2 -92 5 -83 3 -85 
Inflammation markers 
Urinary monocyte chemoattractant protein-
1:creatinine (picogram per milligram) 
Actual %Change Actual %Change Actual %Change 
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  Placebo plus 60 mg 
prednisone control 
(N=20) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=21) 
Base line 752 -- 1266 -- 806 -- 
Week 4 641 -15 588 -54§ 557 -30 
Week 12 426 -43 373 -70¶ 374 -50 
C-reactive protein (milligram per liter)  Actual %Change Actual %Change Actual %Change 
Base line 9.3 -- 5.9 -- 5.0 -- 
Week 4 2.1 -76 1.9 -68 4.0 -17‖ 
Week 12 3.6 -61 1.3 -77 2.7 -41 
Health-related quality of life endpoints 
 N=10 N=14 N=9 
Short Form-36 version 2 Physical 
Functioning 
Actual %Change Actual %Change Actual %Change 
Base line 67±7 -- 68±8 -- 74±11 -- 
Week 4 71±5 31±30 75±6 61±51 90±6  68±71‖ 
Week 12 72±4 33±31 84±4 83±65 93±3 61±57‖ 
Short Form-36 version 2 Mental Health Actual %Change Actual %Change Actual %Change 
Base line 66±5 -- 62±5 -- 82±7 -- 
Week 4 68±5 4±3 73±6 22±8 79±6 -8±8‖ 
Week 12 65±5 1±8 79±6 34±11¶ 89±4 3±6§ 
EuroQOL-5D-5L visual analogue scale Actual %Change Actual %Change Actual %Change 
Base line 69±5 -- 65±5 -- 69±6 -- 
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  Placebo plus 60 mg 
prednisone control 
(N=20) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=21) 
Week 4 66±5 -3±5 70±5 20±15 80±4  7±7‖ 
Week 12 66±5 -3±6 75±5 28±14 78±4 5±2 
*Plus-minus values are mean±SEM; urinary albumin:creatinine ratio, urinary red blood cell count, and urinary 
monocyte chemoattractant protein-1:creatinine ratio actual values are geometric means, and percentage change from 
base line are ratios of geometric means of visit over base line. Number of patients per group for each end point is as 
indicated in the first row unless otherwise indicated. 
† Primary endpoint: treatment response based on Birmingham Vasculitis Activity Score decrease of at least 50% 
from base line and no worsening in any body system. Avacopan plus 20 mg prednisone group was statistically 
noninferior to control (P=0.002) and avacopan without prednisone was also noninferior to control (P=0.01) 
‡Renal response was assessed in patients with hematuria and albuminuria at base line, and was defined as an 
improvement in renal parameters, i.e., an increase in estimated glomerular filtration rate, a decrease in urinary red 
blood cell count, and a decrease in urinary albumin:creatinine ratio 
§ P<0.01 for comparison of avacopan vs. control  
¶ P<0.001 for comparison of avacopan vs. control 
‖ P<0.05 for comparison of avacopan vs. control 
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Table 3. Safety Results for 12-Week Treatment Period 
 Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=22) 
Patients with any adverse event—no. 
(%) 
21 (91) 19 (86) 21 (96) 
Patients with any Grade 3 or greater 
adverse event—no. (%) 
2 (9) 2 (9) 2 (9) 
Deep vein thrombosis 0 1 (5) 0 
Febrile infection 0 1 (5) 0 
Hepatic and pancreatic enzymes 
increased 
0 0 1 (5) 
Pneumonia 1 (4) 0 0 
Renal vasculitis 1 (4) 0 0 
Renal impairment 0 0 1 (5) 
Patients with any serious adverse 
event*—no. (%) 
4 (17) 3 (14) 8 (36) 
Vasculitis 1 (4) 1 (5) 3 (14) 
Infection 1 (4) 1 (5) 1 (5) 
Back pain and vertebral fracture 1 (4) 0 0 
C-reactive protein increase 0 0 1 (5) 
Dehydration 1 (4) 0 0 
Hematuria 0 1 (5) 0 
Hepatic and pancreatic enzymes 
increased 
0 0 1 (5) 
Musculoskeletal chest pain 0 1 (5) 0 
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 Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=22) 
Rash 0 0 1 (5) 
Renal impairment 0 0 1 (5) 
Patients with any adverse effect 
potentially related to 
glucocorticoids—no. (%) 
15 (65) 4 (18) 11 (50) 
Psychiatric disorders†—no. (%) 6 (26) 2 (9) 1 (5) 
New-onset or worsening 
hypertension‡—no. (%) 
5 (26) 2 (9) 8 (36) 
New-onset or worsening diabetes 
mellitus/hyperglycemia§—no. (%) 
4 (17) 0 1 (5) 
Weight gain more than 10 kg—no. 
(%) 
2 (9) 1 (5) 0 
Bone fractures—no. (%) 1 (4) 0 0 
Cataracts—no. (%) 1 (4) 0 0 
Serious infections—no. (%) 1 (4) 1 (5) 1 (5) 
Safety laboratory abnormalities¶ 
Lymphopenia 
Grade 2 1 (4) 1 (5) 3 (14) 
Grade 3  0 1 (5) 3 (14) 
ALT increase, Grade 2 1 (4) 1 (5) 1 (5) 
Bilirubin increase, Grade 3 0 0 1 (5) 
Creatine phosphokinase increase, 
Grade 3 
0 1 (5) 0 
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*Serious adverse events were defined as any adverse event that resulted in death, was immediately life threatening, 
required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, was a birth defect, 
or was an important event that might jeopardize the patient or might have required intervention to prevent any of the 
above. 
†All adverse events of psychosis, anxiety, amnesia, convulsions, delirium, dementia, depression, mania, emotional 
instability, irritability, euphoria, hallucinations, impaired cognition, increased motor activity, insomnia, memory loss, 
mania, mood swings, neuritis, neuropathy, paresthesia, personality changes, restlessness, schizophrenia, vertigo, or 
withdrawal behavior. 
‡Defined as adverse events of hypertension, worsening hypertension, or high blood pressure, plus all patients with a 
systolic blood pressure increase of at least 20 mm Hg, and greater than 140 mm Hg (systolic), or diastolic blood 
pressure increase of at least 10 mm Hg, and greater than 90 mm Hg (diastolic), on at least two consecutive study 
visits. 
§All adverse events of hyperglycemia, diabetes mellitus, increased blood glucose, plus all patients with a fasting 
blood glucose post baseline that is above the upper limit of normal on at least 2 consecutive study visits. 
¶Grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, published: May 28, 
2009 (v4.03: June 14, 2010), U.S. Department of Health and Human Services, National Institutes of Health, National 
Cancer Institute. 
 
87 Patients were assessed for eligibility 
67 Patients were randomized 
12 in step 1 
14 in step 2 
41 in step 3a 
20 patients were ineligible 
5 for insufficient disease activity 
3 for WBC count too low 
3 for too severe disease 
2 for ANCA negative 
2 for eGFR too low 
1 for glucocorticoid dose too high 
1 for positive viral screening test 
1 for active infection 
1 for PT/PTT time abnormal 
1 for lack of patient motivation 
23 Were assigned to receive placebo 
plus 60 mg prednisone 
4 in step 1 
6 in step 2 
13 in step 3 
22 Were assigned to receive CCX168 
plus 20 mg prednisone 
8 in step 1 
14 in step 3 
22 Were assigned to receive CCX168 
plus prednisone placebo 
8 in step 2 
14 in step 3 
2 Patients discontinued before week 12 
2 Withdrew informed consent 
20 Patients were analyzed 
3 Patients were excluded from 
analysis because they did not have 
a post baseline on-treatment BVAS  
No patients discontinued before week 12 
22 Patients were analyzed 21 Patients were analyzed 
1 Patient was excluded from 
analysis because he did not have a 
post baseline on-treatment BVAS  
2 Patients discontinued before week 12 
1 Due to AE (high hepatic and 
pancreatic enzymes) 
1 Due to Investigator decision 
18 Patients completed the 12-week 
follow-up period 
3 Discontinued between week 12 
and 24 
1 Withdrew informed consent 
2 Due to AEs (vasculitis in both) 
19 Patients completed the 12-week 
follow-up period 
3 Discontinued between week 12 
and 24 
2 Due to AEs (vasculitis in both) 
1 Due to rescue medication 
18 Patients completed the 12-week 
follow-up period 
2 Discontinued between week 12 
and 24 
1 Withdrew informed consent 
1 Due to AE (relapse MPA) 
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Supplemental Material 
Participating investigators in CLEAR Trial: 
Austria—K. Lhotta, Landeskrankenhaus Feldkirch, Feldkirch; 
Belgium—M. Jadoul, Cliniques Universitaires Saint-Luc, Brussels; R. Hellemans, Antwerp 
University Hospital - Universitair Ziekenhuis Antwerpen, Edegem (Antwerp); P. Peeters, 
University Hospital Gent, Gent; J. Sennesael, University Hospital Brussels, Brussels; C. Bovy, 
Centre Hospitalier Universitaire de Liège, Liège; B. Sprangers, Universitair Ziekenhuis Leuven, 
Leuven; 
Czech Republic— V.Tesar, Department of Nephrology, General University Hospital, Prague; O. 
Viklicky, Institute for Clinical and Experimental Medicine (IKEM), Prague; 
France—C. Rigothier, CHU Bordeaux - Hospital Pellegrin, Bordeaux; L. Vrigneaud, Centre 
Hospitalier de Valenciennes, Valenciennes; A. Karras, Georges Pompidou European Hospital, 
Paris; 
Germany— M. Schaier and M. Zeier, Universitaetsklinikum Heidelberg – Nephrologie, 
Heidelberg; H. Mehling, Charite, Experimental and Clinical Research Center (ECRC), Berlin; V. 
Burst and F. Grundmann, Universitaetsklinik Koeln, Cologne; C. Hugo, Universitaetsklinikum 
Carl Gustav Carus, Technische Universitaet, Dresden; R. Voll, University Hospital Freiburg, 
Freiburg; 
Hungary—I. Szombati, Buda Clinic, Budapest; 
The Netherlands—A. Rutgers, Universitair Medisch Centrum Groningen, Groningen; O. 
Bredewold, Leids Universitair Medisch Centrum, Leiden; P. Van Daele, Erasmus Medisch 
Centrum, Rotterdam;  
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Poland—K. Ciechanowski, Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych, 
Samodzielny Publiczny Szpital Kliniczny nr 2 Pomorskiej Akademii Medycznej w Szczecinie, 
Szczecin; 
Sweden—A. Bruchfeld, Karolinska University Hospital, Stockholm; D. Selga, Njurkliniken 
Lund, Skanes Universitetssjukhus, Lund; K. Westman, Skane University Hospital, Malmo; M. 
Segelmark, Linköping University, Linköping; 
United Kingdom—D. Jayne, Addenbrooke’s Hospital - Cambridge University Hospitals, 
Cambridge; A. Salama, Royal Free Hospital, London: L. Harper, University of Birmingham - 
Queen Elizabeth Hospital, Birmingham; R. Luqmani, Nuffield Orthopaedic Centre, Oxford; M. 
Venning and P. Hamilton, University of Manchester, Royal Infirmary, Manchester. 
 
Study Inclusion and Exclusion Criteria 
Eligible patients were at least 18 years old and had newly diagnosed or relapsing granulomatosis 
with polyangiitis (Wegener’s) or microscopic polyangiitis according to the Chapel Hill 
Consensus Conference definitions1, that required cyclophosphamide treatment (steps 1 and 2), 
cyclophosphamide or rituximab (step 3), were PR3 or MPO-ANCA positive or ANCA positive 
by indirect immunofluorescence, had an eGFR of at least 20 mL/min/1.73 m2, had biopsy-proven 
renal vasculitis or hematuria (greater than 30 red blood cells per high power field or greater than 
2+ by urine dipstick) plus albuminuria (at least 0.5 g/g creatinine) for steps 1 and 2, or had at 
least one major or three non-major items, or at least two renal items on the BVAS version 32 for 
step 3. Since the BVAS version 3 does not designate “major” items, these were selected to be 
consistent with the BVAS WG3.  
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Patients were excluded if they had severe disease (including rapidly progressive 
glomerulonephritis, alveolar hemorrhage leading to grade 3 hypoxia, rapid-onset mononeuritis 
multiplex, or central nervous system involvement), any other autoimmune disease, coagulopathy 
or bleeding disorder, had received cyclophosphamide within 12 weeks, rituximab within 12 
months prior to screening (or 6 months with B-cell reconstitution, CD19 count >0.01x109/L), 
cumulative dose of intravenous glucocorticoids greater than 3 g within 12 weeks, or oral 
glucocorticoids of more than 10 mg per day prednisone equivalent for more than 6 weeks prior to 
screening. 
Study Assessments 
The Birmingham Vasculitis Activity Score (BVAS) version 3 was completed during 
screening, day 1 (base line), and weeks 4, 12, 16, and 24. The BVAS score was calculated 
according to the guidelines for the BVAS version 32. First morning urine samples for albumin, 
monocyte chemoattractant protein-1 (MCP-1), and creatinine were collected at day 1 and weeks 
1, 2, 4, 8, 12, 16, and 24. Urine albumin was measured by a nephelometric assay, MCP-1 by 
ELISA, and creatinine by a kinetic colorimetric assay in a central laboratory (Medpace Reference 
Laboratory, Belgium). Serum creatinine, for eGFR calculation, and urine red blood cell 
microscopy were performed regularly over the study course. eGFR (according to the Modified 
Diet in Renal Disease equation)=175×(serum creatinine, mg/dL)-1.154×(age, years) -0.203×(0.742 if 
female)×(1.212 if black). The Medical Outcomes Study Short Form-36 version 2 (SF-36) survey 
and the EuroQOL-5-D-5L (EQ-5D-5L) questionnaire were completed (in step 3 only) at day 1, 
and weeks 4, 12, and 24. The vasculitis damage index (VDI)4 was completed on day 1 and weeks 
12 and 24.  
Safety was monitored at each study visit by assessing adverse events and laboratory data. 
The incidence of adverse effects commonly associated with glucocorticoid use, including 
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psychiatric disorders, hypertension, diabetes mellitus/hyperglycemia, weight gain, bone fractures, 
cataracts, and serious infections was summarized. These effects were selected based on guidance 
from AAV experts, as well as those reported in patients with AAV5,6. For example, infection 
resulted in 50% of deaths in AAV studies5, gastrointestinal bleeding in 5%5. Also diabetes 
mellitus (8%5 and 11%6), fractures (3%5 and 15%6), and cataracts (9%6) occur frequently.    
Patient compliance with taking study medication was assessed based on returned capsule counts 
at each study visit. 
Criteria for adjusting the cyclophosphamide dose: 
The cyclophosphamide dose was determined by four factors: subject age, estimated 
glomerular filtration rate, WBC count at the study visit, and WBC count nadir in between dose 
pulses (where applicable): 
Age:  
• If <60 years, a full dose was given (unless influenced by the other three factors); 
• If 60 to 70 years, the dose was reduced by 2.5 mg/kg; 
• If > 70 years, the dose was reduced by 5 mg/kg. 
Estimated glomerular filtration rate: 
• If ≥30 ml/min, a full dose was given (unless influenced by the other three factors); 
• If <30 ml/min, the dose was reduced by 2.5 mg/kg. 
WBC count at the time of cyclophosphamide dose (local lab WBC counts):  
• If ≥4 x 109/L, a full dose was given (unless influenced by the other three factors); 
• If 2 to 3.9 x 109/L, the dose was reduced by 25%; 
• If <2 x 109/L, the dose was withheld until the WBC count increased to above 3 x 109/L. 
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WBC count nadir in between cyclophosphamide doses:  
• If >3 x 109/L, a full dose was given (unless influenced by the other three factors); 
• If 2 to 3 x 109/L, the dose was reduced by 20%; 
• If 1 to 1.9 x 109/L, the dose was reduced by 40%;  
• If <1 x 109/L, the next dose was withheld and further dosing was only given if the WBC 
was >3 x 109/L. 
Data Monitoring Committee 
An independent external Data Monitoring Committee (DMC) oversaw the study and periodically 
reviewed safety data. The DMC advised the sponsor regarding transition between steps. At all its 
visits, the DMC recommended unchanged continuation of the study. 
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Supplemental Table 1. Pre-Specified Prednisone Dose Tapering Schedule for the Three 
Treatment Groups 
 
Study Week Placebo plus 60 mg 
prednisone* control 
Avacopan plus 20 mg 
prednisone 
Avacopan 
without 
prednisone 
1 60 mg (or 45 mg for <55 kg 
subjects) 
20 mg (or 15 mg for <55 kg 
subjects) 
0† 
2 45 mg 15 mg 0 
3 30 mg 10 mg 0 
4-6 25 mg 10 mg 0 
7-8 20 mg 5 mg 0 
9-10 15 mg 5 mg 0 
11-14 10 mg 5 mg 0 
15-20 5 mg 0 0 
≥21 0 0 0 
* Prednisone was supplied to study centers as 20 mg and 5 mg tablets, over-encapsulated with 
hard gelatin capsules. 
†Placebo prednisone was given as matching gelatin capsules.  
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Supplemental Table 2. Treatment Response Based on BVAS for Subgroups* 
 Placebo plus 60 mg 
prednisone control 
(N=23) 
Avacopan plus 20 mg 
prednisone 
(N=22) 
Avacopan without 
prednisone 
(N=22) 
All Patients* 14 / 20 (70) 19 / 22 (86) 17 / 21 (81) 
Disease Status 
Newly diagnosed 
patients 
11 / 15 (73) 13 / 15 (87) 13 / 15 (87) 
Relapsing disease 3 / 5 (60) 6 / 7 (86) 4 / 6 (67) 
Type of AAV 
GPA 5 / 10 (50) 11 / 11 (100) 10 / 12 (83) 
MPA 7 / 8 (88) 7 / 9 (78) 6 / 8 (75) 
ANCA Status 
Anti-PR3 positive 6 / 10 (60) 10 / 10 (100) 6 / 8 (75) 
Anti-MPO positive 7 / 10 (70) 9 / 12 (75) 11 / 13 (85) 
Disease Location 
Renal ± other disease 13 / 19 (68) 18 / 21 (86) 16 / 20 (80) 
Only non-renal 
disease 
1 / 1 (100) 1 / 1 (100) 1 / 1 (100) 
Background Treatment 
Cyclophosphamide 11 / 17 (65) 14 / 17 (82) 14 / 16 (88) 
Rituximab 3 / 3 (100) 5 / 5 (100) 3 / 5 (60) 
*Results are shown for n / N (%), where n = the number of treatment responders and N = the number of 
patients in the subgroup of patients specified. Treatment response is defined as a decrease from baseline to 
week 12 in BVAS of at least 50 percent and no worsening in any body system. AAV = ANCA-associated 
vasculitis; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; PR3 = proteinase 3; 
MPO = myeloperoxidase. 
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Supplemental Table 3. Summary Results of the Short Form-36 version 2 Domains by Study 
Visit* 
Domain Study Visit High Dose Steroids 
SOC Control 
(N=10) 
Avacopan + 
Low-Dose 
Steroids 
(N=14) 
Avacopan + No 
Steroids 
(N=9) 
Role Physical Base line 46±10 34±7 60±14 
Week 4 51±7 48±8 76±12 
Week 12 59±5 71±6 84±9 
Bodily Pain  Base line 68±10 61±8 72±12 
Week 4 67±9 75±7  83±9† 
Week 12 81±6 81±6 93±7 
General Health Base line 45±7 55±4 66±5 
Week 4 48±5 60±5 52±6 
Week 12 51±4 59±5 62±8 
Vitality Base line 41±6 40±5 55±11 
Week 4 47±5 53±7 60±10 
Week 12 46±4    62±5†    71±8‡ 
Social Functioning Base line 74±6 46±6 82±12 
Week 4 68±10 70±6 84±12 
Week 12 80±7 81±5 96±4 
Mental Health Base line 66±5 62±5 82±7 
Week 4 68±5 73±6 79±6 
Week 12 65±5    79±6‡    89±4‡ 
Reported Health 
Transition (decrease 
shows 
improvement)§ 
Base line 3.8±0.3 3.9±0.4 3.4±0.3 
Week 4 4.0±0.2 3.2±0.4 3.5±0.4 
Week 12 3.8±0.3 2.9±0.2† 2.9±0.4 
*Results are shown for n, the number of patients with a measurement at the time point, and 
mean±SEM. The physical functioning and role emotional domain results are presented in 
Table 2. 
† P<0.05,  ‡ P<0.01 for change or percent change from baseline differences between avacopan 
and control groups. 
§A decrease in Reported Health Transition corresponds to an improvement in health compared to 
one year ago. 
